Dear patients and physician friends:

In order to implement the requirements of the Drug Administration Law of the People's Republic of China on establishing a drug surveillance system and fulfill the main responsibility of drug surveillance for drug marketing authorization holders, the National Medical Products Administration officially issued the "Quality Management Standards for Drug Surveillance" on May 13, 2021, and implemented it from December 1, 2021.

Our company has established a drug surveillance management system in accordance with the "Quality Management Standards for Drug Surveillance". In accordance with regulatory requirements, we have established the Drug Safety Committee of Nanjing Daoqun Pharmaceutical R&D Co., Ltd. and set up a Drug Surveillance Department to undertake the reporting and monitoring of adverse reactions of our company's drug Jinqi Jiangtang Capsules.

The contact information for work is as follows:

The scope of adverse drug reaction reports includes adverse reactions of qualified drugs that are unrelated to the intended use of the drug under normal usage and dosage, as well as other adverse events caused by drug quality issues or that may be related to over indications, over dosage, contraindications, medication errors, etc.

Before using this product (Jinqi Jiangtang Capsules), please read this safety notice carefully and strictly follow the instructions and dosage requirements in the product manual. At the same time, pay attention to relevant precautions and medication instructions for special populations to avoid drug interactions and minimize the probability of adverse reactions.

The adverse reactions, contraindications, and precautions of this product are as follows:

If you experience any (including the above) clinical adverse reactions/events while using our company's Jinqi hypoglycemic capsules, please contact our drug vigilance department (hotline 400-860-8006) as soon as possible, or send your feedback information to the drug vigilance work email（ pv@daoqun.cn ）.

In order to report to the higher authorities on time within the regulatory deadline, please cooperate with us to verify and investigate the key information of relevant cases (drug information, patient information, adverse reaction related information, reporter information, etc.), work together to promote drug safety work, and ensure the safety of drug use for the general public.

Nanjing Daoqun Pharmaceutical R&D Co., Ltd

June 14th, 2024